Dasatinib Suppresses TGFβ-Mediated Epithelial–Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis
- 453 Downloads
Transforming growth factor β (TGFβ)-mediated epithelial–mesenchymal transition (EMT) of alveolar epithelial cells contributes to pulmonary fibrosis. Dasatinib (DAS), a potent and broad-spectrum tyrosine kinase inhibitor, has been widely studied as an anti-cancer agent. However, the therapeutic application of DAS for pulmonary fibrosis has not been clarified. Our purpose here is to investigate the effect of DAS on TGFβ1-induced EMT in human alveolar and bronchial epithelial cells in vitro and to evaluate the efficacy of DAS on lung fibrosis in vivo.
TGFβ1-stimulated human alveolar epithelial (A549) and bronchial epithelial (BEAS-2B) cells were treated with or without DAS in vitro. Murine pulmonary fibrosis model was generated by injection of bleomycin (BLM).
A549 and BEAS-2B cells exposed to TGFβ1 underwent EMT, as indicated by downregulation of epithelial protein E-cadherin and induction of the mesenchymal proteins, fibronectin and type I and type IV collagen. These effects were dramatically suppressed by DAS treatment, which also prevented Smad2 and Smad3 phosphorylation. DAS inhibited TGFβ1-induced cell motility and migration. Furthermore, DAS administration significantly attenuated lung fibrosis in mice by histological analysis. Treatment with DAS also significantly reduced the levels of collagen and fibronectin and phosphorylation of Smad2 in the lung tissues of the murine model.
These findings suggest that DAS inhibited TGFβ-mediated EMT of alveolar and bronchial epithelial cells and attenuated BLM-induced lung fibrosis in mice by suppressing the TGFβ/Smad pathway. DAS may be a promising and novel anti-fibrotic agent for preventing lung fibrosis.
KeywordsDasatinib Pulmonary fibrosis Epithelial mesenchymal transition TGFβ
Idiopathic pulmonary fibrosis
Transforming growth factor
Epithelial mesenchymal transition
Quantitative polymerase chain reaction
We appreciate the advice and expertise of Ms. Etsuko Kobayashi, Juntendo University Graduate School of Medicine.
This study was supported by JSPS KAKENHI Grant Number 26461200. This study was also funded by Research Grants from the Satoshi Okamoto Memorial Foundation of Pulmonary Fibrosis, Japan Research Foundation for Clinical Pharmacology, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Yokoyama Foundation for Clinical Pharmacology.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest for this work.
All animal experiments were carried out in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology (Notice No. 71, 2006) and approved by the Committee for Animal Experimentation of Juntendo University with the Approval No. 290031.
Research Involving Human Participants
This article does not contain any studies with human participants performed by any of the authors.
- 27.Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H et al (2015) Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action. Mol Cancer 14:199CrossRefPubMedPubMedCentralGoogle Scholar